AACR Previews Research from Annual Meeting 2018

In less than a month, the AACR Annual Meeting 2018 will kick off in Chicago, Illinois. The meeting is expected to draw about 22,000 attendees, including cancer researchers, clinicians, and advocates.

As always, the meeting features a wide range of high-impact science, featuring presentations on all aspects of basic and translational cancer research, including immunotherapy, precision medicine, artificial intelligence, liquid biopsy, early detection, cancer interception, prevention, cancer disparities, and survivorship.

Read More

AACR Annual Meeting 2017: The Patient Perspective

The American Association for Cancer Research (AACR) Annual Meeting 2017 brought some of the world’s greatest scientific minds to Washington, D.C., to address research challenges in cancer. But significant findings also came from cancer patient advocates and survivors who attended the meeting.

Read More

AACR Annual Meeting 2017: Challenging the Dogma of Treating IDH-mutant Cancers With IDH Inhibitors

Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to that of BRCA-mutant tumors and are, therefore, more likely to respond better to PARP inhibitors than to IDH inhibitors.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More

AACR Annual Meeting 2017: If You Can’t Drug It, Degrade It – A Protein Degradation Technology to Tackle Undruggable Oncoproteins

Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers in the field of oncology drug development.

Read More